Literature DB >> 25174644

Improving treatment of children with acute lymphoblastic leukemia in developing countries through technology sharing, collaboration and partnerships.

Gaston K Rivera1, Raul C Ribeiro.   

Abstract

Cure rates for pediatric acute lymphoblastic leukemia differ markedly in higher- and lower-income countries due to disparate hospital infrastructure and resources. Where means are limited, treatment-related mortality is higher and compliance may be suboptimal. Upfront risk assignment is aimed at individualizing therapy according to presenting features in order to avoid over- or under-treatment. However, the necessary technical resources and expertise are not always readily available. The authors provide suggestions for management of childhood acute lymphoblastic leukemia in developing nations. To improve patient care locally, the authors recommend that communication technology be used to sustain partnerships between sponsoring and partner pediatric oncology programs. The aims of these collaborations should be to prioritize resources, identify existing problems and reduce treatment intensity and hence treatment-related morbidity and mortality in patients at lower risk of relapse.

Entities:  

Keywords:  acute lymphoblastic leukemia; lower- and higher-income countries; minimal residual disease; partner institution; reduced intensity chemotherapy; risk-directed therapy; sponsor institution

Mesh:

Substances:

Year:  2014        PMID: 25174644      PMCID: PMC4174393          DOI: 10.1586/17474086.2014.949233

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN: 1747-4094            Impact factor:   2.929


  19 in total

1.  Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area.

Authors:  Scott C Howard; Marcia Pedrosa; Mecneide Lins; Arli Pedrosa; Ching-Hon Pui; Raul C Ribeiro; Francisco Pedrosa
Journal:  JAMA       Date:  2004-05-26       Impact factor: 56.272

2.  Development of a regional flow cytometry center for diagnosis of childhood leukemia in Central America.

Authors:  S C Howard; D Campana; E Coustan-Smith; F G Antillon; M Bonilla; L Fu; C-H Pui; R C Ribeiro; J A Wilimas; R Lorenzana
Journal:  Leukemia       Date:  2005-03       Impact factor: 11.528

3.  Five-year follow-up of "total therapy" of childhood lymphocytic leukemia.

Authors:  D Pinkel
Journal:  JAMA       Date:  1971-04-26       Impact factor: 56.272

4.  Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia.

Authors:  Albert Moghrabi; Donna E Levy; Barbara Asselin; Ronald Barr; Luis Clavell; Craig Hurwitz; Yvan Samson; Marshall Schorin; Virginia K Dalton; Steven E Lipshultz; Donna S Neuberg; Richard D Gelber; Harvey J Cohen; Stephen E Sallan; Lewis B Silverman
Journal:  Blood       Date:  2006-09-26       Impact factor: 22.113

5.  A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome.

Authors:  Elaine Coustan-Smith; Raul C Ribeiro; Patricia Stow; Yinmei Zhou; Ching-Hon Pui; Gaston K Rivera; Francisco Pedrosa; Dario Campana
Journal:  Blood       Date:  2006-03-14       Impact factor: 22.113

6.  Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital.

Authors:  G K Rivera; D Pinkel; J V Simone; M L Hancock; W M Crist
Journal:  N Engl J Med       Date:  1993-10-28       Impact factor: 91.245

7.  Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002.

Authors:  Jan Stary; Martin Zimmermann; Myriam Campbell; Luis Castillo; Eduardo Dibar; Svetlana Donska; Alejandro Gonzalez; Shai Izraeli; Dragana Janic; Janez Jazbec; Josip Konja; Emilia Kaiserova; Jerzy Kowalczyk; Gabor Kovacs; Chi-Kong Li; Edina Magyarosy; Alexander Popa; Batia Stark; Yahia Jabali; Jan Trka; Ondrej Hrusak; Hansjörg Riehm; Giuseppe Masera; Martin Schrappe
Journal:  J Clin Oncol       Date:  2013-12-16       Impact factor: 44.544

8.  Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.

Authors:  Allen R Chauvenet; Paul L Martin; Meenakshi Devidas; Stephen B Linda; Beverly A Bell; Joanne Kurtzberg; Jeanette Pullen; Mark J Pettenati; Andrew J Carroll; Jonathan J Shuster; Bruce Camitta
Journal:  Blood       Date:  2007-04-18       Impact factor: 22.113

9.  The Latin American Center for Pediatric Oncology Nursing Education: development, implementation, and accomplishments.

Authors:  Sara W Day; Lorena Segovia; Paola Viveros; Mohammad R Alqudimat; Gaston K Rivera
Journal:  Cancer Nurs       Date:  2013 Sep-Oct       Impact factor: 2.592

10.  Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.

Authors:  Maurizio Aricò; Maria Grazia Valsecchi; Carmelo Rizzari; Elena Barisone; Andrea Biondi; Fiorina Casale; Franco Locatelli; Luca Lo Nigro; Matteo Luciani; Chiara Messina; Concetta Micalizzi; Rosanna Parasole; Andrea Pession; Nicola Santoro; Anna Maria Testi; Daniela Silvestri; Giuseppe Basso; Giuseppe Masera; Valentino Conter
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544

View more
  7 in total

1.  The Impact of Prospective Telemedicine Implementation in the Management of Childhood Acute Lymphoblastic Leukemia in Recife, Brazil.

Authors:  Francisco Pedrosa; Faisal Shaikh; Gaston Rivera; Raul Ribeiro; Ibrahim Qaddoumi
Journal:  Telemed J E Health       Date:  2017-04-19       Impact factor: 3.536

Review 2.  Therapies on the horizon for childhood acute lymphoblastic leukemia.

Authors:  William L Carroll; Stephen P Hunger
Journal:  Curr Opin Pediatr       Date:  2016-02       Impact factor: 2.856

Review 3.  Global Pediatric Oncology: Lessons From Partnerships Between High-Income Countries and Low- to Mid-Income Countries.

Authors:  Raul C Ribeiro; Federico Antillon; Francisco Pedrosa; Ching-Hon Pui
Journal:  J Clin Oncol       Date:  2015-11-17       Impact factor: 44.544

4.  Reduced-dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study.

Authors:  Francisco Pedrosa; Elaine Coustan-Smith; Yinmei Zhou; Cheng Cheng; Arli Pedrosa; Mecneide Mendes Lins; Marcia Pedrosa; Norma Lucena-Silva; Alessandra Maria de Luna Ramos; Ester Vinhas; Gaston K Rivera; Dario Campana; Raul C Ribeiro
Journal:  Blood       Date:  2020-04-23       Impact factor: 25.476

5.  Septicemia after chemotherapy for childhood acute lymphoblastic leukemia in China: A multicenter study CCCG-ALL-2015.

Authors:  Yiping Zhu; Rong Yang; Jiaoyang Cai; Jie Yu; Yanjing Tang; Yumei Chen; Ningling Wang; Hailong He; Xuedong Wu; Frankie W T Cheng; Lirong Sun; Yingyi He; Xiuli Ju; Xin Tian; Qun Hu; Runming Jin; Kaili Pan; Yongjun Fang; Xiaowen Zhai; Hui Jiang; Chi-Kong Li
Journal:  Cancer Med       Date:  2020-01-28       Impact factor: 4.452

6.  Impact of an animal-assisted therapy programme on physiological and psychosocial variables of paediatric oncology patients.

Authors:  Nathiana B Silva; Flávia L Osório
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

7.  Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia.

Authors:  Nur Melani Sari; Lulu E Rakhmilla; Muhammad Hasan Bashari; Zulfan Zazuli; Nur Suryawan; Susi Susanah; Lelani Reniarti; Harry Raspati; Eddy Supriyadi; Gertjan J L Kaspers; Ponpon Idjradinata
Journal:  Asian Pac J Cancer Prev       Date:  2021-07-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.